Alvotech (ALVO)

Alvotech (ALVO) to Release Earnings on Tuesday - Defense World

Defense World

Alvotech SA expected to post a loss of 8 cents a share - Earnings Preview - XM

XM

Alvotech S.A. Annual General Meeting to be held June 7, - GlobeNewswire

GlobeNewswire

Alvotech S.A. Annual General Meeting to be held June 7, 2024 - Marketscreener.com

Marketscreener.com

Alvotech S.A. Annual General Meeting to be held June 7, 2024 - Yahoo Finance

Yahoo Finance

ScPharmaceuticals, Inc. (SCPH) Reports Q1 Loss, Lags Revenue Estimates

Zacks Investment Research

Orchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Misses Revenue Estimates

Zacks Investment Research

Alvotech Announces Webcast of First Quarter 2024 Financial Results on May 22, 2024, at 8:00 am EDT (12 noon GMT) - GlobeNewswire

GlobeNewswire

Alvotech Announces Webcast of First Quarter 2024 Financial Results on May 22, 2024, at 8:00 am EDT (12 noon GMT) - GlobeNewswire

GlobeNewswire

Alvotech Announces Webcast of First Quarter 2024 Financial Results on May 22, 2024, at 8: 00 am EDT (12 noon GMT) - Marketscreener.com

Marketscreener.com

Alvotech Announces Webcast of First Quarter 2024 Financial Results on May 22, 2024, at 8:00 am EDT (12 noon GMT) - Yahoo Finance

Yahoo Finance

Alvotech (NASDAQ:ALVOW) Shares Down 12.3% - Defense World

Defense World

Evolus, Alvotech gain as Barclays raises to Ovrweight - MSN

MSN

Alvotech (NASDAQ:ALVO): Is Breakeven Near? - Simply Wall St

Simply Wall St

Alvotech (NASDAQ:ALVO) shareholders have endured a 19% loss from investing in the stock a year ago - Yahoo Canada Shine On

Yahoo Canada Shine On

Alvotech : General Meeting Alvotech - Convening Notice (AGM 2024) - Marketscreener.com

Marketscreener.com

Alvotech, collaborators prep for Humira biosimilar US launch for AS - Ankylosing Spondylitis News

Ankylosing Spondylitis News

ALVO Stock Earnings: Alvotech Reported Results for Q4 2023 - MSN

MSN

Alvotech to manufacture Humira biosimilar for Quallent Pharmaceuticals - Drug Store News

Drug Store News

Alvotech to manufacture Humira biosimilar for Quallent - BioProcess Insider

BioProcess Insider

Alvotech Announces Participation at BofA Securities Healthcare Conference 2024 - GlobeNewswire

GlobeNewswire

Alvotech Announces Participation at BofA Securities Healthcare Conference 2024 - GlobeNewswire

GlobeNewswire

Alvotech tekur þátt í heilbrigðisráðstefnu BofA Securities í Bandaríkjunum

GlobeNewswire Inc.

Alvotech Announces Participation at BofA Securities Healthcare Conference 2024 - Yahoo Finance UK

Yahoo Finance UK

U.S. Commercialization Agreement with Quallent to Drive - GlobeNewswire

GlobeNewswire

Alvotech semur við Quallent Pharmaceuticals um markaðssetningu á hliðstæðu við Humira í Bandaríkjunum

GlobeNewswire Inc.

U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free ... - Yahoo Finance

Yahoo Finance

Gilead Sciences (GILD) Reports Q1 Loss, Tops Revenue Estimates

Zacks Investment Research

Alvotech: Consider Buying As Positive Q1 Earnings Release Likely (NASDAQ:ALVO) - Seeking Alpha

Seeking Alpha

Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi ... - GlobeNewswire

GlobeNewswire

Alvotech kynnir jákvæða niðurstöðu rannsóknar á sjúklingum sem sýnir sömu klínísku virkni líftæknilyfjahliðstæðunnar AVT05 og Simponi® (golimumab)

GlobeNewswire Inc.

Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi ... - GlobeNewswire

GlobeNewswire

Alvotech Signs U.S. Agreement - European Pharmaceutical Manufacturer

European Pharmaceutical Manufacturer

Alvotech moves to bring its Humira biosimilar to US market - GlobalData

GlobalData

Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to ... - Marketscreener.com

Marketscreener.com

Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)

GlobeNewswire Inc.

Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to ... - Yahoo Finance UK

Yahoo Finance UK

Teva, Alvotech Secure FDA Approval for Stelara Biosimilar with Early 2025 Launch - BioSpace

BioSpace

Teva and Alvotech announce FDA approved SELARSDI injection - TipRanks.com - TipRanks

TipRanks

Alvotech and Teva win FDA approval of Stelara copy - The Pharma Letter

The Pharma Letter

Alvotech hlýtur markaðsleyfi í Bandaríkjunum fyrir Selarsdi (ustekinumab-aekn) líftæknilyfjahliðstæðu við Stelara

GlobeNewswire Inc.

FDA approves Alvotech biosimilar of J&J top-selling drug Stelara (NYSE:TEVA) - Seeking Alpha

Seeking Alpha

Turkey's Abdi İbrahim Allies With mAbxience For 'Unprecedented' Technology Transfer - Generics Bulletin

Generics Bulletin

Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024

GlobeNewswire Inc.

Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024

GlobeNewswire Inc.

Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024 - GlobeNewswire

GlobeNewswire

Amgen Introduces Second Stelara Rival In Canada - Generics Bulletin

Generics Bulletin

Aehr Test Systems Reports Preliminary Results, Joins Dyne Therapeutics, United Airlines And Other Big Stocks Moving Lower On Monday

Benzinga

Alvotech (NASDAQ:ALVO) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock? - Simply Wall St

Simply Wall St

Alvotech tilkynnir um útgáfu eigin hlutabréfa

GlobeNewswire Inc.